### Edgar Filing: Karp Daniel - Form 4


Karp Daniel										
Form 4	2010									
February 14										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION						Т	OMB APPROVAL			
	UNITED	SIALES						Number:	3235-0287	
Check th	Check this box Washington, D.C. 20549				Expires:	January 31,				
if no longer subject to Section 16. Form 4 or				CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					2005 average urs per	
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Karp Daniel			2. Issuer Name <b>and</b> Ticker or Trading Symbol <b>BIOGEN INC. [BIIB]</b>				5. Relationship of Reporting Person(s) to Issuer			
							(Check all applicable)			
(Last)	(First)	(Middle)		of Earliest T	ransaction		D' (	100	<b>7</b> O	
BIOGEN INC., 225 BINNEY ST.			(Month/Day/Year) 02/12/2019				Director 10% Owner X Officer (give title Other (specify below) below) EVP, Corporate Development			
(Street) CAMBRIDGE, MA 02142			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check			
							Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
CAMDRID	OL, MA 02142						Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	<ul><li>(A)</li><li>or</li><li>(D) Price</li></ul>	Transaction(s) (Instr. 3 and 4)			
D 1 D		C 1 1	c				· · · · · ·			
Keminder: Rej	port on a separate lin	ie for each cl	ass of sec	urities bene	Perso	ons who res	or indirectly. spond to the colle tained in this form		SEC 1474 (9-02)	

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	nof Derivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

#### Edgar Filing: Karp Daniel - Form 4



## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Karp Daniel BIOGEN INC. 225 BINNEY ST. CAMBRIDGE, MA 02142			EVP, Corporate Development			
Signatures						
/s/ Suzanne Murray, Attorney in Fact for Daniel Karp			02/14/2019			
<u>**</u> Signature of Reporting	Person		Date			
E I						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.

(1) The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.